Skip to content
Boca Raton City Online – Lifestyle
Author:
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
May 19, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 12, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
April 29, 2026
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
April 21, 2026
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
April 17, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
1
2
Next Page
→